What will be the price of dacomitinib/dacomitinib after it is covered by medical insurance in 2024?

Dacomitinib (Dacomitinib) is a cancer drug used to treat adults with advanced or spread non-small cell lung cancer (NSCLC). Dacomitinib can be used alone, and only in patients who have a specific mutation in the gene for a protein called epidermal growth factor receptor (EGFR). Dacomitinib contains the active substance dacomitinib, which belongs to a group of cancer drugs called tyrosine kinase inhibitors. It blocks the activity of EGFR, which normally controls cell growth and division. In lung cancer cells, EGFR is often overactive, causing cancer cells to grow uncontrollably. By blocking EGFR, dacomitinib helps reduce the growth and spread of cancer. In clinical studies, dacomitinib has been shown to be more effective than gefitinib (gefitinib; another drug for the treatment of non-small cell lung cancer) in prolonging patients' survival without worsening of the disease.

DacomitinibThe original drug has been approved and marketed in China by the State Food and Drug Administration, and has also entered the scope of Class B medical insurance through the relevant policies of the National Medical Insurance Administration. The common specifications sold in ChinaThe price per box is 15mg*30 tablets The price may be more than 1,000 yuan, and medical insurance can be used for reimbursement for patients who meet the indications, that is, patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion mutation or exon 21 L858R substitution mutation. Due to different reimbursement ratios or reimbursement policies in each region, the prices for patients after reimbursement by medical insurance may vary, and patients who do not meet the conditions cannot be reimbursed. For specific information, please consult the hospital or local medical insurance bureau.